logo
Twitter
Discord
Email
logo
Alpha Teknova, Inc.

Alpha Teknova, Inc.

NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Contact Information
2451 Bert Dr., Hollister, CA, 95023, United States
831-637-1100
www.teknova.com
Market Cap
$238.20M
P/E (TTM)
-13.1
38.7
Dividend Yield
--
52W High
$10.37
52W Low
$3.94
52W Range
8%
3.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q3 2025 Data

Revenue

$10.45M+9.17%
4-Quarter Trend

EPS

-$0.08-52.94%
4-Quarter Trend

FCF

-$2.27M-5.15%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Rises 7.2% Nine month revenue reached $30.54M, marking a $2.06M increase, primarily driven by Lab Essentials segment growth.
Gross Profit Nearly Doubles Nine month gross profit surged 99.8% to $10.20M; gross margin improved to 33.4% from 17.9%.
Operating Loss Significantly Narrows Net loss for nine months reduced by 40.5% to $12.50M, reflecting better cost management across operations.
Operating Expenses Decline Total operating expenses fell 11.9% to $22.56M for nine months, aided by workforce reduction savings.

Risk Factors

Continued Operating Losses Incurred $12.50M net loss for nine months; company may never achieve or maintain future profitability.
Potential Stock Price Drop Large volume of outstanding common stock available for immediate resale risks significant market price decline.
Supplier Concentration Risk Relies on limited suppliers for raw materials; no long-term supply arrangements exist for critical components.
Economic Uncertainty Impact Inflation and interest rate changes create uncertainty, potentially causing customers to reduce or delay product orders.

Outlook

Future Expense Increase Expected Expect operating expenses to increase due to ongoing activities like attracting personnel and expanding manufacturing capacity.
Capital Raising Flexibility Shelf registration effective July 2025 allows offering up to $225M in securities based on future capital needs.
Credit Facility Covenants Must meet minimum net revenue of $39.0M and minimum cash requirement of $8.0M under credit agreement.
Focus on Capacity Expansion Investing in infrastructure to improve efficiency, expand capacity at facilities, and build overall brand market presence.

Peer Comparison

Revenue (TTM)

Ironwood Pharmaceuticals, Inc.IRWD
$338.99M
-10.4%
Canopy Growth CorporationCGC
$277.21M
-1.1%
Aurora Cannabis Inc.ACB
$250.10M
+25.0%

Gross Margin (Latest Quarter)

AC Immune SAACIU
100.0%
+2494.6 pp
Silence Therapeutics plcSLN
80.4%
+223.3 pp
SOPHiA GENETICS SASOPH
67.0%
-1.2 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IRWD$510.81M6.0-33.8%53.8%
ACIU$330.97M-5.2-49.0%2.6%
SLN$322.61M-1.9-85.9%-0.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+4.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $10.45M+9.2%
    |
    EPS: $-0.08-52.9%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $10.29M+7.0%
    |
    EPS: $-0.07-48.6%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $9.80M+5.4%
    |
    EPS: $-0.09-56.5%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 7, 2025|
    Revenue: $37.75M+2.9%
    |
    EPS: $-0.57+50.9%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $9.58M+17.2%
    |
    EPS: $-0.17-50.0%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $9.61M-16.6%
    |
    EPS: $-0.13-48.0%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $9.29M+1.9%
    |
    EPS: $-0.20-35.5%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 27, 2024|
    Revenue: $36.68M-11.4%
    |
    EPS: $-1.16+31.4%
    Miss